JP2013520990A5 - - Google Patents

Download PDF

Info

Publication number
JP2013520990A5
JP2013520990A5 JP2012556068A JP2012556068A JP2013520990A5 JP 2013520990 A5 JP2013520990 A5 JP 2013520990A5 JP 2012556068 A JP2012556068 A JP 2012556068A JP 2012556068 A JP2012556068 A JP 2012556068A JP 2013520990 A5 JP2013520990 A5 JP 2013520990A5
Authority
JP
Japan
Prior art keywords
antibody
antibody fragment
mab
seq
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012556068A
Other languages
English (en)
Japanese (ja)
Other versions
JP5911813B2 (ja
JP2013520990A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/000415 external-priority patent/WO2011109108A1/en
Publication of JP2013520990A publication Critical patent/JP2013520990A/ja
Publication of JP2013520990A5 publication Critical patent/JP2013520990A5/ja
Application granted granted Critical
Publication of JP5911813B2 publication Critical patent/JP5911813B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012556068A 2010-03-04 2011-03-04 Ｃｄ２０に対するモノクローナル抗体 Expired - Fee Related JP5911813B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31044010P 2010-03-04 2010-03-04
US61/310,440 2010-03-04
PCT/US2011/000415 WO2011109108A1 (en) 2010-03-04 2011-03-04 Monoclonal antibodies directed to cd20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016068492A Division JP2016179978A (ja) 2010-03-04 2016-03-30 Ｃｄ２０に対するモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2013520990A JP2013520990A (ja) 2013-06-10
JP2013520990A5 true JP2013520990A5 (enExample) 2014-04-17
JP5911813B2 JP5911813B2 (ja) 2016-04-27

Family

ID=44542488

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012556068A Expired - Fee Related JP5911813B2 (ja) 2010-03-04 2011-03-04 Ｃｄ２０に対するモノクローナル抗体
JP2016068492A Pending JP2016179978A (ja) 2010-03-04 2016-03-30 Ｃｄ２０に対するモノクローナル抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016068492A Pending JP2016179978A (ja) 2010-03-04 2016-03-30 Ｃｄ２０に対するモノクローナル抗体

Country Status (6)

Country Link
EP (1) EP2542262A4 (enExample)
JP (2) JP5911813B2 (enExample)
AU (2) AU2011221553B2 (enExample)
BR (1) BR112012022338A2 (enExample)
CA (1) CA2791560A1 (enExample)
WO (1) WO2011109108A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569460B2 (en) 2009-03-25 2013-10-29 Vet Therapeutics, Inc. Antibody constant domain regions and uses thereof
BR112012022342A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
AU2012252153B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
US9790280B2 (en) * 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use
EP3416984B1 (en) 2016-02-18 2021-03-31 Elanco US Inc. Chimeric canine anti-cd20 antibody
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
JP2021059499A (ja) * 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
WO2024158001A1 (ja) 2023-01-25 2024-08-02 日本全薬工業株式会社 イヌのｂ細胞リンパ腫の治療方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3919830B2 (ja) * 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
JP3087696B2 (ja) 1997-07-25 2000-09-11 日本電気株式会社 分散メモリ型マルチプロセッサ・システム制御方法およびコンピュータ読み取り可能な記録媒体
ATE365539T1 (de) 1999-12-30 2007-07-15 Dana Farber Cancer Inst Inc Proteoliposomen, die ein integral membranprotein mit einer oder memhreren transmembrandomänen enthalten
US7261890B2 (en) * 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
WO2004043344A2 (en) * 2002-11-07 2004-05-27 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
US20080299546A1 (en) * 2004-02-10 2008-12-04 Nihon University Canine Cd20 Gene
WO2006007202A2 (en) * 2004-05-28 2006-01-19 Idexx Laboratories, Inc Canine cd20 compositions
GB0707640D0 (en) 2007-04-20 2007-05-30 Strathclyde Acoustic deterrence
US8337842B2 (en) 2008-09-04 2012-12-25 Vet Therapeutics, Inc. Monoclonal antibodies

Similar Documents

Publication Publication Date Title
JP2013520999A5 (enExample)
JP2013520990A5 (enExample)
CY1123791T1 (el) Μονοκλωνικο αντισωμα ιντερλευκινης-31
DOP2013000129A (es) PROTEÍNAS DE UNIÓN AL TNF-a.
NZ588713A (en) Antibodies to receptor of advanced glycation end products (rage) and uses thereof
JOP20200078A1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
SG194466A1 (en) Non-human animals expressing antibodies having a common light chain
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
WO2011050106A3 (en) Anti-cd3 antibody dosing in autoimmune disease
BRPI0916945A2 (pt) métodos para tratar uma doença auto-imune ou distúrbio inflamatório em um indivíduo humano, para tratar esclerose múltipla em um indivíduo, e para identificar anticorpos, anticorpo humano, humanizado ou quimérico isolado ou um fragmento de ligação de antígeno do mesmo, e, proteína de ligação isolada.
RU2016100892A (ru) Антитела против tweakr и их применение
JP2014503189A5 (enExample)
HRP20251181T1 (hr) Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
AR077594A1 (es) Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
BRPI0821682A2 (pt) Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.
JP2014061000A5 (enExample)
MX379533B (es) Ratones de cadena ligera universal humanizados.
MX353278B (es) Raton con cadena ligera comun.
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
MX2015012540A (es) Ratón de cadena ligera común.
CU24597B1 (es) Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
MX341921B (es) Proteinas de union a antigeno.
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2013538057A5 (enExample)